Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
41351070 (PubMed )
Supplement: 12885_2025_15187_MOESM1_ESM.zip › Supp_Table_1.xlsx › Sheet1
Multiplexed in vivo base editing identifies functional gene-variant-context interactions.
Acosta J et al.
Biorxiv : the Preprint Server for Biology, 2025
40060482 (PubMed )
Supplement: media-4.xlsx › Table_S2A
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM et al.
Cancer Research Communications, 2024
38282550 (PubMed )
Supplement: crc-23-0312-s02.xlsx › Fig3B_EC_data
Analysis of Genetic Alterations in Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma With Whole-Exome Sequencing.
Zhao A et al.
Frontiers in Oncology, 2022
35359413 (PubMed )
Supplement: Table_2.xlsx › DataS1
Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.
Cao C et al.
Aging, 2021
34837690 (PubMed )
Supplement: aging-13-203710-s004.xlsx › Sheet1
ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis.
Yachida N et al.
Scientific Reports, 2020
32868822 (PubMed )
Supplement: 41598_2020_71273_MOESM1_ESM.docx
Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer.
Suhaimi SS et al.
Frontiers in Pharmacology, 2018
The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan S et al.
Anticancer Research, 2011
ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC et al.
The New England Journal of Medicine, 2010
Select a paper to view details